One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
A pharmacological overview of aprepitant for the prevention of postoperative nausea and vomiting
Andrew Padilla & Ashraf S Habib
doi : 10.1080/17512433.2023.2209722
Expert Review of Clinical Pharmacology, Volume 16, Issue 6 (2023)
Post-operative nausea and vomiting (PONV) affects 30% of all patients undergoing surgery and up to 80% of high-risk patients. Antiemetics for PONV prophylaxis target a variety of receptor systems, with varying degrees of efficacy and side effect profile. Neurokinin −1 receptor antagonists are the most recent class of compounds investigated for PONV prophylaxis, with aprepitant being the only one currently approved for this indication.
Breaking down barriers for prescribing and using hormone therapy for the treatment of menopausal symptoms: an experts’ perspective
Serge Rozenberg, Nick Panay, Marco Gambacciani, Antonio Cano, Sarah Gray & Katrin Schaudig
doi : 10.1080/17512433.2023.2219056
Around 80% of women suffer menopause-related symptoms that affect their daily activities and quality of life. Menopausal hormone therapy (MHT) has proven to be beneficial in relieving these symptoms. Nevertheless, only 20/30% of symptomatic women seek treatment. This has resulted in neglect of a generation of healthcare professionals’ (HCPs) education in menopausal medicine and a reduction in the prescription of MHT in menopausal women for over two decades.
Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
Alberto Ortiz, Roberto Alc?zar Arroyo, Pedro Pablo Casado Escribano, Beatriz Fern?ndez-Fern?ndez, Francisco Mart?nez Debén, Juan Diego Mediavilla, Alfredo Michan-Do?a, Maria Jose Soler & Jose Luis Gorriz
doi : 10.1080/17512433.2023.2213888
Patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) are at high risk of CKD progression and cardiovascular events. Despite treatment with renin-angiotensin system inhibitors and SGLT-2 inhibitors, the residual risk is substantial. There is preclinical and clinical evidence supporting a key role of mineralocorticoid receptor in cardiorenal injury in T2DM.
Optimizing outcomes and managing adverse events in locally advanced or metastatic urothelial cancer: a clinical pharmacology perspective
Pratap Singh, Anand Rotte, Anthony A. Golsorkhi & Sandhya Girish
doi : 10.1080/17512433.2023.2219446
Bladder cancer (BC) is the sixth most common type of cancer with epithelial/urothelial and non-urothelial origins. Urothelial carcinoma (UC) involves neoplastic cells of epithelial origin and accounts for 90% of all BC cases. Current review aims to discuss the latest advances and challenges in the treatment of UC with an emphasis on clinical pharmacology considerations.
TYK2 as a novel therapeutic target in psoriasis
Sarah Elyoussfi, Shraddha S Rane, Steve Eyre & Richard B Warren
doi : 10.1080/17512433.2023.2219054
Psoriasis is a chronic inflammatory skin disease affecting approximately 60 million people worldwide. Genome-wide association studies (GWAS) have allowed identification of novel therapeutic targets in psoriasis including tyrosine kinase 2 (TYK2) where an exonic variant within the gene increases the risk of developing psoriasis.
Snakebite-associated thrombotic microangiopathy: a spotlight on pharmaceutical interventions
Tina Noutsos & Geoffrey K Isbister
doi : 10.1080/17512433.2023.2220963
Snakebite is a neglected public health issue causing death and disability, disproportionately affecting tropical and subtropical resource poor countries globally. Snakebite-associated thrombotic microangiopathy (TMA) occurs in a subset of snakebites and is associated with acute kidney injury (sometimes requiring renal replacement therapy) and a risk of chronic kidney disease.
Significant predictors for olanzapine pharmacokinetics: a systematic review of population pharmacokinetic studies
Jue-Hui Mao, Lu Han, Xiao-Qin Liu & Zheng Jiao
doi : 10.1080/17512433.2023.2219055
Olanzapine is widely used for treating schizophrenia and bipolar I disorder. Due to its high pharmacokinetic variability, several population pharmacokinetic studies have been performed to identify factors contributing to the variability and thus facilitate individualized dosing. This review aims to provide a comprehensive overview of published population pharmacokinetic studies and explore potential covariates.
Efficacy and safety of oliceridine treatment in patients with postoperative pain: a systematic review and meta-analysis of randomized controlled trials
Jingwen Niu, Wenmin Hu, Yuntao Lu & Hui Tang
doi : 10.1080/17512433.2023.2213889
Our aim was to conduct a systematic review and meta-analysis to examine the efficacy and safety of oliceridine in patients with postoperative pain.
Efficacy and safety of compound glycyrrhizin in the patients with vitiligo: a systematic review and meta-analysis
Ming Li, Lujing Xiang & Yan Li
doi : 10.1080/17512433.2023.2213887
Compound glycyrrhizin (CG) is widely used to treat vitiligo in China, and the efficacy and adverse events (AEs) of CG for vitiligo need further analysis. This study aimed to systematically reevaluate the efficacy and safety of CG in the patients with vitiligo.
